COVAXIN® for Children: Study demonstrates robust safety and immunogenicity in 2-18 Volunteers.

COVAXIN Ò is the one of the first COVID-19 vaccines in the world to generate data in 2-18 year age group. · Phase II/III, Open-Label, Multi-centre Study was conducted to evaluate the Safety, Reactogenicity, and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN ® ) in healthy children and adolescents in the 2-18 age group. · Whole-Virion inactivated SARS-CoV-2 Vaccine (BBV152) has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study . Neutralizing antibodies in children on an average 1.7 times higher than in adults. · No serious adverse event was reported. Pain at the injection site was the most commonly reported adverse event. No cases of myocarditis or blood clots were reported, as expected with inactivated vaccines. Mumbai, December 31, 2021: Bharat Biotech Interna...